Aclaris Therapeutics, Inc.
US ˙ NasdaqGS ˙ US00461U1051

SecurityACRS / Aclaris Therapeutics, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Ownership 0.50%
Citadel Advisors Llc ownership in ACRS / Aclaris Therapeutics, Inc.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (ACRS) in the form of stock options. The firm currently holds call options representing 466,400 of underlying shares valued at $1,749,000 USD and put options representing 102,300 of underlying shares valued at $383,625 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2024-11-14 2024-11-14 13G/A 0.50 -93.42
2024-02-14 2024-02-14 13G/A 7.60 49.02
2023-09-05 2023-09-05 13G 5.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ACRS / Aclaris Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 2,249,319 1,044,038 86.62 8,435 132.53 0.0012
2026-02-17 2025-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 1,205,281 -227,396 -15.87 3,628 33.25 0.0005
2025-11-14 2025-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 1,432,677 288,871 25.26 2,722 67.61 0.0004
2025-08-14 2025-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 1,143,806 21,725 1.94 1,624 -5.36 0.0003
2025-05-15 2025-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 1,122,081 1,066,734 1,927.36 1,717 1,152.55 0.0003
2025-02-14 2024-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 55,347 -309,220 -84.82 137 -67.30 0.0000
2024-11-14 2024-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 364,567 -510,649 -58.35 419 -56.44 0.0001
2024-08-14 2024-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 875,216 -54,787 -5.89 963 -16.57 0.0002
2024-05-15 2024-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 930,003 -4,458,786 -82.74 1,153 -79.62 0.0002
2024-02-14 2023-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 5,388,789 2,031,549 60.51 5,658 -75.40 0.0011
2023-11-14 2023-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 3,357,240 744,166 28.48 22,997 -15.13 0.0049
2023-08-14 2023-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 2,613,074 -494,690 -15.92 27,098 7.78 0.0056
2023-05-15 2023-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 3,107,764 2,032,724 189.08 25,142 48.49 0.0055
2023-02-14 2022-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 1,075,040 -43,377 -3.88 16,932 -3.82 0.0040
2022-11-14 2022-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 1,118,417 165,345 17.35 17,603 32.30 0.0040
2022-08-15 2022-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 953,072 -19,128 -1.97 13,305 -20.62 0.0034
2022-05-16 2022-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 972,200 -39,572 -3.91 16,761 13.94 0.0035
2022-02-14 2021-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 1,011,772 -51,845 -4.87 14,711 -23.16 0.0030
2021-11-15 2021-09-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 1,063,617 -163,776 -13.34 19,145 -11.17 0.0040
2021-08-16 2021-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 1,227,393 -99,956 -7.53 21,553 -35.56 0.0048
2021-05-21 2021-03-31 13F/A-1 ACLARIS THERAPEUTICS COM 00461U105 1,327,349 1,286,007 3,110.66 33,449 12,427.72 0.0082
2021-05-17 2021-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 1,327,349 1,286,007 33,449 0.0082
2021-02-16 2020-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 41,342 16,238 64.68 267 310.77 0.0001
2020-11-16 2020-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 25,104 25,104 65 0.0000
2020-08-14 2020-06-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 0 -51,250 -100.00 0 -100.00
2020-05-15 2020-03-31 13F ACLARIS THERAPEUTICS Cmn 00461U105 51,250 24,479 91.44 53 3.92 0.0000
2020-02-14 2019-12-31 13F ACLARIS THERAPEUTICS Cmn 00461U105 26,771 -47,963 -64.18 51 -36.25 0.0000
2019-11-14 2019-09-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 74,734 42,281 130.28 80 12.68 0.0000
2019-08-14 2019-06-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 32,453 -156,388 -82.81 71 -93.72 0.0000
2019-05-15 2019-03-31 13F ACLARIS THERAPEUTICS Cmn 00461U105 188,841 -365,497 -65.93 1,131 -72.39 0.0006
2019-02-14 2018-12-31 13F ACLARIS THERAPEUTICS Cmn 00461U105 554,338 -328,026 -37.18 4,096 -68.03 0.0022
2018-11-13 2018-09-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 882,364 14,134 1.63 12,812 -26.11 0.0057
2018-08-14 2018-06-30 13F/A-1 ACLARIS THERAPEUTICS Cmn 00461U105 868,230 -28,607 -3.19 17,339 10.36 0.0086
2018-08-10 2018-06-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 868,230 -28,607 17,339
2018-05-14 2018-03-31 13F/A-1 ACLARIS THERAPEUTICS Cmn 00461U105 896,837 748,422 504.28 15,712 329.29 0.0086
2018-05-11 2018-03-31 13F ACLARIS THERAPEUTICS Cmn 00461U105 896,837 748,422 15,712
2018-02-09 2017-12-31 13F ACLARIS THERAPEUTICS Cmn 00461U105 148,415 -93,601 -38.68 3,660 -41.41 0.0022
2017-11-09 2017-09-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 242,016 208,429 620.56 6,247 585.73 0.0048
2017-08-11 2017-06-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 33,587 -17,357 -34.07 911 -40.03 0.0008
2017-05-12 2017-03-31 13F ACLARIS THERAPEUTICS Cmn 00461U105 50,944 50,944 1,519 0.0014
2017-02-10 2016-12-31 13F ACLARIS THERAPEUTICS Cmn 00461U105 0 -9,303 -100.00 0 -100.00
2017-01-31 2016-09-30 13F/A-1 ACLARIS THERAPEUTICS Cmn 00461U105 9,303 9,303 238 0.0002
2016-11-10 2016-09-30 13F ACLARIS THERAPEUTICS Cmn 00461U105 9,303 238 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ACLARIS THERAPEUTICS COM Call 466,400 -59.03 1,749 -48.95 n/a n/a n/a
2026-02-17 2025-12-31 13F ACLARIS THERAPEUTICS COM Call 1,138,400 3,427 n/a n/a n/a
2025-08-14 2025-06-30 13F ACLARIS THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F ACLARIS THERAPEUTICS COM Call 5,100 -75.71 8 -86.54 n/a n/a n/a
2025-02-14 2024-12-31 13F ACLARIS THERAPEUTICS COM Call 21,000 500.00 52 1,200.00 n/a n/a n/a
2024-11-14 2024-09-30 13F ACLARIS THERAPEUTICS COM Call 3,500 -73.48 4 -71.43 n/a n/a n/a
2024-08-14 2024-06-30 13F ACLARIS THERAPEUTICS COM Call 13,200 -64.80 15 -69.57 n/a n/a n/a
2024-05-15 2024-03-31 13F ACLARIS THERAPEUTICS COM Call 37,500 116.76 46 155.56 n/a n/a n/a
2024-02-14 2023-12-31 13F ACLARIS THERAPEUTICS COM Call 17,300 -92.32 18 -98.83 n/a n/a n/a
2023-11-14 2023-09-30 13F ACLARIS THERAPEUTICS COM Call 225,300 109.00 1,543 38.14 n/a n/a n/a
2023-08-14 2023-06-30 13F ACLARIS THERAPEUTICS COM Call 107,800 -8.10 1,118 17.83 n/a n/a n/a
2023-05-15 2023-03-31 13F ACLARIS THERAPEUTICS COM Call 117,300 1,313.25 949 629.23 n/a n/a n/a
2023-02-14 2022-12-31 13F ACLARIS THERAPEUTICS COM Call 8,300 131 n/a n/a n/a
2022-05-16 2022-03-31 13F ACLARIS THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-14 2021-12-31 13F ACLARIS THERAPEUTICS COM Call 20,700 -3.27 301 -21.82 n/a n/a n/a
2021-11-15 2021-09-30 13F ACLARIS THERAPEUTICS Cmn Call 21,400 -50.00 385 -48.80 n/a n/a n/a
2021-08-16 2021-06-30 13F ACLARIS THERAPEUTICS COM Call 42,800 -30.41 752 -51.48 n/a n/a n/a
2021-05-21 2021-03-31 13F/A ACLARIS THERAPEUTICS COM Call 61,500 -10.61 1,550 248.31 n/a n/a n/a
2021-05-17 2021-03-31 13F ACLARIS THERAPEUTICS COM Call 61,500 1,550 n/a n/a n/a
2021-02-16 2020-12-31 13F ACLARIS THERAPEUTICS COM Call 68,800 381.12 445 1,102.70 n/a n/a n/a
2020-11-16 2020-09-30 13F ACLARIS THERAPEUTICS COM Call 14,300 37 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ACLARIS THERAPEUTICS COM Put 102,300 384 n/a n/a n/a
2025-08-14 2025-06-30 13F ACLARIS THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F ACLARIS THERAPEUTICS COM Put 32,000 -2.14 49 -40.74 n/a n/a n/a
2025-02-14 2024-12-31 13F ACLARIS THERAPEUTICS COM Put 32,700 3,170.00 81 8,000.00 n/a n/a n/a
2024-11-14 2024-09-30 13F ACLARIS THERAPEUTICS COM Put 1,000 -69.70 1 -66.67 n/a n/a n/a
2024-08-14 2024-06-30 13F ACLARIS THERAPEUTICS COM Put 3,300 -79.25 4 -84.21 n/a n/a n/a
2024-05-15 2024-03-31 13F ACLARIS THERAPEUTICS COM Put 15,900 -52.54 20 -45.71 n/a n/a n/a
2024-02-14 2023-12-31 13F ACLARIS THERAPEUTICS COM Put 33,500 -69.07 35 -95.28 n/a n/a n/a
2023-11-14 2023-09-30 13F ACLARIS THERAPEUTICS COM Put 108,300 25.35 742 -17.21 n/a n/a n/a
2023-08-14 2023-06-30 13F ACLARIS THERAPEUTICS COM Put 86,400 -36.47 896 -18.64 n/a n/a n/a
2023-05-15 2023-03-31 13F ACLARIS THERAPEUTICS COM Put 136,000 4,287.10 1,100 2,191.67 n/a n/a n/a
2023-02-14 2022-12-31 13F ACLARIS THERAPEUTICS COM Put 3,100 49 n/a n/a n/a
2022-02-14 2021-12-31 13F ACLARIS THERAPEUTICS Cmn Put 0 -100.00 0 -100.00 n/a n/a n/a
2021-11-15 2021-09-30 13F ACLARIS THERAPEUTICS Cmn Put 22,900 120.19 412 125.14 n/a n/a n/a
2021-08-16 2021-06-30 13F ACLARIS THERAPEUTICS COM Put 10,400 -67.50 183 -77.30 n/a n/a n/a
2021-05-21 2021-03-31 13F/A ACLARIS THERAPEUTICS COM Put 32,000 123.78 806 766.67 n/a n/a n/a
2021-05-17 2021-03-31 13F ACLARIS THERAPEUTICS COM Put 32,000 806 n/a n/a n/a
2021-02-16 2020-12-31 13F ACLARIS THERAPEUTICS COM Put 14,300 93 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.